News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acceleron Pharma And Celgene (CELG) Report New Interim Clinical Data From Phase 2 Trial Of Sotatercept In Beta-Thalassemia At 2013 American Society of Hematology Annual Meeting



12/9/2013 9:33:33 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner Celgene reported new interim data at the 55th American Society of Hematology (ASH) Annual Meeting of sotatercept in patients with beta-thalassemia.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES